Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome®) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients-Reference-Cited by-同舟云学术

Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome®) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients

Published:2008-08-16 Issue:2 Volume:88 Page:151-158
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Camera Andrea,Rinaldi Ciro R.,Palmieri Salvatore,Cantore Nicola,Mele Giuseppina,Mettivier Vincenzo,Miraglia Eustachio,Mastrullo Lucia,Grimaldi Francesco,Luciano Luigia,Guerriero Anna,Rotoli Bruno,Ferrara Felicetto

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-008-0571-z.pdf

Reference29 articles.

1. Keating S, de Witte T, Suciu S, Willemze R, Hayat M, Labar B, Resegotti L, Ferrini PR, Caronia F, Dardenne M, Solbu G, Petti MC, Vegna ML, Mandelli F, Zittoun RA (1998) The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. Br J Haematol 102:1344–1353

2. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G et al (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 332:217–223

3. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, Harrison G (2002) The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 118:385–400

4. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood 92:2322–2333

5. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89:3323–3329

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia;Blood;2021-02-11

2. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review;Expert Review of Clinical Pharmacology;2019-02-06

3. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review;Annals of Hematology;2018-04-21

4. Diagnosis and Treatment of Adult Acute Myeloid Leukemia Other than Acute Promyelocytic Leukemia;Neoplastic Diseases of the Blood;2017-09-22

5. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine;Biomedicine & Pharmacotherapy;2017-06